ArticleBMJ public health2025
Epidemiological perspectives of amyloidosis in Argentina: a cohort study analysing incidence and mortality patterns among a population affiliated to a medical care programme.
Article in BMJ public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Data on the epidemiology of amyloidosis are scarce worldwide, making it difficult to understand its true incidence and mortality. Aim: The aim of this study is to estimate the incidence and mortality rate of systemic amyloidosis in people affiliated to a Medical Care Program in the city of Buenos Aires, Argentina. Methods: This is a hospital-based prospective study. All affiliates over 17 years to the Medical Care Program of the Hospital Italiano de Buenos Aires, and incident cases and deaths due to amyloidosis from the Institucional Amyloidosis Registry from 1 January 2011 to 31 December 2022 were included. Incidence and mortality rates were reported per million person-year with their respective 95% CIs. Crude, standardised and stratified rates were determined. Results: During the study period, the crude incidence rate was 63 (95% CI 52 to 76) and the crude mortality rate was 31 (95% CI 23 to 40) cases per million person-year, with the wild-type transthyretin amyloidosis (ATTRwt) subtype having the highest rates. Men were more affected, especially from the age of 70 years onwards. In addition, an increase in the incidence and mortality rate was observed throughout the period studied. Conclusion: The results of this study indicate that amyloidosis remains a rare disease but with an increase in incidence in recent years, especially in elderly people. This underlines the importance of further research in epidemiology for a better understanding of the pathology and its evolution.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.